美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Invesco Nasdaq Biotechnology ETF

34.23

-0.0200-0.06%

成交量：1.13萬

成交額：38.83萬

市值：9,515.94萬

市盈率：- -

高：34.62

開：34.39

低：34.20

收：34.25

52周最高：36.84

52周最低：23.42

股本：278.00萬

流通股本：278.00萬

量比：0.58

換手率：0.41%

股息：0.26

股息率：0.75%

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

三重動力支撐創新藥企「強者更強」

通用電氣可再生能源表示，有意開展更多併購交易，且幾乎可以肯定交易將圍繞自身核心業務展開。

石藥集團SYH2069注射液用於治療成人2型糖尿病的II期臨床試驗在中國首個研究中心啓動

吉利德科學擴大六項免許可費自願授權協議，力推每年一次HIV預防藥Lenacapavir

上海萊士(002252.SZ)：「SR604注射液」進入Ⅲ期臨床試驗

上海萊士：SR604注射液進入Ⅲ期臨床試驗

Sling Therapeutics 籌集 1.23 億美元，用於推進甲狀腺相關眼病藥物的研發

石藥集團(01093)：SYH2069注射液用於治療成人2型糖尿病的II期臨床試驗在中國首個研究中心正式啓動

智通财经网

苑東生物：EP-0226片完成I期臨床試驗推進II期籌備

陽光諾和(688621.SH)：在研項目BTP0427的臨床試驗申請獲得批准

陽光諾和：BTP0427規格I、II獲臨床試驗批准

ST百靈(002424.SZ)子公司糖寧通絡乳膏獲批臨床試驗

ST百靈：全資子公司獲2026年藥物臨床試驗批准通知書

港股異動 | 恒瑞醫藥(01276)尾盤漲近4% 同日獲兩份臨床試驗批准覆蓋銀屑病和卒中預防

創新藥概念股表現活躍

香港施政報告：邀請廣深企業參與大學城建設河套大灣區國際臨床試驗所投入運作

江小涓：這個數據大家不要吃驚，未來幾年還要漲

凤凰网港股

創新藥概念局部走強恒瑞醫藥（01276）漲2.74% 機構料企業扭虧節點到來

百時美施貴寶就安進擬推出的Opdivo生物類似藥提起訴訟

恒瑞醫藥(01276.HK)：注射用瑞卡西單抗獲得藥物臨床試驗批准通知書

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.imtigers.com/hant/stock/IBBQ/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"IBBQ","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IBBQ\",,,,,undefined,":{"symbol":"IBBQ","market":"US","secType":"STK","nameCN":"Invesco Nasdaq Biotechnology ETF","latestPrice":34.23,"timestamp":1789587284275,"preClose":34.25,"halted":0,"volume":11268,"delay":0,"changeRate":-0.0005839416058395073,"floatShares":2780001,"shares":2780001,"eps":0,"marketStatus":"交易中","change":-0.02,"latestTime":"09-16 15:37:51 EDT","open":34.39,"high":34.62,"low":34.1992,"amount":388300.733712,"amplitude":0.012286,"askPrice":34.26,"askSize":2379,"bidPrice":34.23,"bidSize":700,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"盤後交易","tradingStatus":3,"beginTime":1789588800000},"marketStatusCode":2,"adr":0,"exchange":"NASDAQ","adjPreClose":34.25,"sharesOutstanding":2520001,"nav":34.76286,"aum":96640785.56286,"dividendRate":0.007505,"bidAskSpread":0,"preHourTrading":{"tag":"盘前","latestPrice":34.28,"preClose":34.25,"latestTime":"09:29 EDT","volume":69,"amount":2360.8497660000003,"timestamp":1789565397037,"change":0.03,"changeRate":0.000876,"amplitude":0.008175},"postHourTrading":{"tag":"盘后","latestPrice":34.25,"preClose":34.25,"latestTime":"19:30 EDT","volume":6387,"amount":218773.45,"timestamp":1789515006181,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.576551,"impliedVol":0.0643,"impliedVolPercentile":0.0598},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IBBQ\",,,,,undefined,":{"symbol":"IBBQ","floatShares":2780001,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.576551,"shares":2780001,"dividePrice":0.2569,"high":34.62,"amplitude":0.012286,"preClose":34.25,"low":34.1992,"week52Low":23.42,"pbRate":"--","week52High":36.84,"institutionHeld":0,"latestPrice":34.23,"committee":-0.293286,"eps":0,"divideRate":0.007505,"volume":11268,"delay":0,"ttmEps":0,"open":34.39,"prevYearClose":28.3962,"prevWeekClose":34.472,"prevMonthClose":35.4742,"prevQuarterClose":32.66,"fiveDayClose":34.9277,"twentyDayClose":34.6197,"sixtyDayClose":30.4995},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IBBQ\",params:#limit:5,,,undefined,":[{"date":"2026-06-22","symbol":"IBBQ","amount":0.03422,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-22","defaultRemindTime":1782135000000,"name":"Invesco Nasdaq Biotechnology ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-26","payableDate":"2026-06-22","currency":"USD","dateTimestamp":1782100800000,"payDate":"2026-06-26"},{"date":"2026-03-23","symbol":"IBBQ","amount":0.03609,"announcedDate":"2026-03-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-03-23","defaultRemindTime":1774272600000,"name":"Invesco Nasdaq Biotechnology ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-03-27","payableDate":"2026-03-23","currency":"USD","dateTimestamp":1774238400000,"payDate":"2026-03-27"},{"date":"2025-12-22","symbol":"IBBQ","amount":0.0906,"announcedDate":"2025-12-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-22","defaultRemindTime":1766413800000,"name":"Invesco Nasdaq Biotechnology ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-26","payableDate":"2025-12-22","currency":"USD","dateTimestamp":1766379600000,"payDate":"2025-12-26"},{"date":"2025-09-22","symbol":"IBBQ","amount":0.09576,"announcedDate":"2025-09-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-22","defaultRemindTime":1758547800000,"name":"Invesco Nasdaq Biotechnology ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-26","payableDate":"2025-09-22","currency":"USD","dateTimestamp":1758513600000,"payDate":"2025-09-26"},{"date":"2025-06-23","symbol":"IBBQ","amount":0.0287,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-23","defaultRemindTime":1750685400000,"name":"Invesco Nasdaq Biotechnology ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-06-27","payableDate":"2025-06-23","currency":"USD","dateTimestamp":1750651200000,"payDate":"2025-06-27"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IBBQ\",market:\"US\",,,undefined,":[{"executeDate":"2021-09-20","recordDate":"2021-09-21","paymentDate":"2021-09-30","value":0.04324,"currency":"USD"},{"executeDate":"2021-12-20","recordDate":"2021-12-21","paymentDate":"2021-12-31","value":0.10511,"currency":"USD"},{"executeDate":"2022-03-21","recordDate":"2022-03-22","paymentDate":"2022-03-31","value":0.03778,"currency":"USD"},{"executeDate":"2022-06-21","recordDate":"2022-06-22","paymentDate":"2022-06-30","value":0.04264,"currency":"USD"},{"executeDate":"2022-09-19","recordDate":"2022-09-20","paymentDate":"2022-09-23","value":0.03769,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IBBQ\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IBBQ\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2668987804","title":"三重動力支撐創新藥企「強者更強」","url":"https://stock-news.laohu8.com/highlight/detail?id=2668987804","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668987804?lang=zh_tw&edition=fundamental","pubTime":"2026-09-17 00:01","pubTimestamp":1789574460,"startTime":"0","endTime":"0","summary":"今年以来，创新药行业分化愈发明显。招商证券统计显示，91家A/H股创新药公司中，2026年上半年共有44家实现盈利，其中盈利额前五的公司占全部盈利公司利润总额的48%。中国创新药跨境BD（商务拓展）同样呈现集中趋势。据动脉智库数据，2026年上半年，中国创新药对外BD的潜在总额达1100亿美元，其中，交易金额体量排名前十的项目的总金额为739.14亿美元，占比在六成以上。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609173876437951.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609173876437951.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["IBBQ","MEDX","159992","BK1161","LNGR","BK1574","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667984205","title":"通用電氣可再生能源表示，有意開展更多併購交易，且幾乎可以肯定交易將圍繞自身核心業務展開。","url":"https://stock-news.laohu8.com/highlight/detail?id=2667984205","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667984205?lang=zh_tw&edition=fundamental","pubTime":"2026-09-16 23:38","pubTimestamp":1789573119,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["DFMC","VCLN","AAUM","BK4588","TBXU","PBPH","PWER","SMOG","ACES","PBW","IYH","UYG","GTPE","ACTV","MMID","PEVC","SDGS","TMED","PRVT","RSPH","PSP","RNRG","FFSM","XLFI","IBBQ","CANC","MNA","HEAT","VXF","IEFN","RFG","SOLR","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667989312","title":"石藥集團SYH2069注射液用於治療成人2型糖尿病的II期臨床試驗在中國首個研究中心啓動","url":"https://stock-news.laohu8.com/highlight/detail?id=2667989312","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667989312?lang=zh_tw&edition=fundamental","pubTime":"2026-09-16 21:55","pubTimestamp":1789566903,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["PSYK","MDTX","IBBJ","IBBQ","BMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164691459","title":"吉利德科學擴大六項免許可費自願授權協議，力推每年一次HIV預防藥Lenacapavir","url":"https://stock-news.laohu8.com/highlight/detail?id=1164691459","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1164691459?lang=zh_tw&edition=fundamental","pubTime":"2026-09-16 20:31","pubTimestamp":1789561872,"startTime":"0","endTime":"0","summary":"吉利德科学宣布，扩大其六项免许可费的自愿授权协议，覆盖其每年仅需注射一次的HIV预防药物Lenacapavir。此举旨在拓宽药物可及性，助力全球抗击艾滋病疫情。通过这一系列协议，吉利德希望加快该长效预防方案在中低收入国家的推广，以应对持续存在的公共卫生挑战。该举措不仅彰显了公司在全球健康公平方面的承诺，也为实现2030年终结艾滋病流行的目标注入新动力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3T34201.USD","IBB","SG9999015952.SGD","LU1023059063.AUD","IE00B7SZLL34.SGD","LU0122379950.USD","LU1934455277.USD","LU2087621335.USD","BK4583","LU1037948541.HKD","LU0861579265.USD","LU0058720904.USD","LU0882574055.USD","IE00BKVL7J92.USD","SG9999015978.USD","IE00BSNM7G36.USD","LU1066051498.USD","LU1571399168.USD","TBXU","TMED","LU2089984988.USD","SG9999015986.USD","LU1430594728.SGD","LU1674673428.USD","GILD","BK4585","LU1585245621.USD","LU0965509101.SGD","LU0965509283.SGD","IE0002270589.USD","LU2468319806.SGD","LU0320765992.SGD","LU1066053197.SGD","LU2324357040.USD","LU0234570918.USD","LU1061106388.HKD","IE00B19Z3581.USD","LU0965508806.USD","LU0859254822.USD","LU0965509010.AUD","BK4139","LU0289739699.SGD","LU2357627491.SGD","LU1037948897.HKD","BK4566","BMED","BK4588","BK4532","IE00BZ1G4Q59.USD","IBBQ","BK4578","BK4568","LU0114720955.EUR","LU1778281490.HKD","MEDI","IE00B19Z3B42.SGD","BK4550","LU0889565916.HKD","BBH","LU1057294990.SGD","LU1934455863.HKD","LU1934455194.USD","LU2112291526.USD","BIB","LU0109394709.USD","LU1674673691.USD","LU0823416689.USD","LU1839511570.USD","SG9999015945.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667988673","title":"上海萊士(002252.SZ)：「SR604注射液」進入Ⅲ期臨床試驗","url":"https://stock-news.laohu8.com/highlight/detail?id=2667988673","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667988673?lang=zh_tw&edition=fundamental","pubTime":"2026-09-16 19:56","pubTimestamp":1789559791,"startTime":"0","endTime":"0","summary":"智通财经APP讯，上海莱士 发布公告，公司在研产品“SR604注射液”于近日在国家药品监督管理局药物临床试验登记与信息公示平台公示了“血友病A/B患者出血发作的预防治疗”Ⅲ期临床试验登记信息，试验名称：评价SR604注射液在有或无抑制物的血友病A/B患者中预防治疗的有效性和安全性的单臂、多中心Ⅲ期临床试验试验目的：评价SR604注射液在有或无抑制物的血友病A/B患者中预防治疗的有效性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1497035.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["PSYK","IBBQ","BK0028","IBBJ","BK0196","BK0188","MDTX","BK0239","BK0046","002252","BMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667498863","title":"上海萊士：SR604注射液進入Ⅲ期臨床試驗","url":"https://stock-news.laohu8.com/highlight/detail?id=2667498863","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667498863?lang=zh_tw&edition=fundamental","pubTime":"2026-09-16 19:51","pubTimestamp":1789559491,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BMED","IBBQ","PSYK","MDTX","IBBJ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667074086","title":"Sling Therapeutics 籌集 1.23 億美元，用於推進甲狀腺相關眼病藥物的研發","url":"https://stock-news.laohu8.com/highlight/detail?id=2667074086","media":"路透中文","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667074086?lang=zh_tw&edition=fundamental","pubTime":"2026-09-16 19:01","pubTimestamp":1789556485,"startTime":"0","endTime":"0","summary":"Sling Therapeutics 筹集 1.23 亿美元，用于推进甲状腺相关眼病药物的研发Kunal Das/Siddhi Mahatole路透9月16日-药物研发公司Sling Therapeutics周三表示，已筹集1.23亿美元，用于推进其用于治疗甲状腺眼病的实验性口服药物的后期临床试验。该疾病会导致眼周发炎和肿胀，进而可能引发眼球突出和视力丧失。作为此次融资协议的一部分，Sling还任命了Forbion的Regina Salvat和Sectoral Asset Management的Franois Beaubien加入其董事会。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260916:nL4T4580NN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0289739699.SGD","IE00B4R5TH58.HKD","LU0109394709.USD","BK4588","LU1061106388.HKD","BK4533","LU0122379950.USD","BK4581","LU0868494617.USD","LU2468319806.SGD","BK4566","IE0002141913.USD","IE00BJJMRZ35.SGD","LU0320765992.SGD","LU1057294990.SGD","BK4139","LU1983299246.USD","LU1023059063.AUD","BIB","LU0058720904.USD","LU1571399168.USD","PBE","LU2112291526.USD","LU0889565916.HKD","BK4585","LU2089984988.USD","BK4534","IBB","TBXU","IE00BJT1NW94.SGD","VRDN","IBBQ","PJP","SG9999001440.SGD","LU2242652126.USD","LU2242646821.SGD","BK4599","IE00B2B36J28.USD","IE0009355771.USD","AMGN","IE00BFTCPJ56.SGD","BBH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667020436","title":"石藥集團(01093)：SYH2069注射液用於治療成人2型糖尿病的II期臨床試驗在中國首個研究中心正式啓動","url":"https://stock-news.laohu8.com/highlight/detail?id=2667020436","media":"智通财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667020436?lang=zh_tw&edition=fundamental","pubTime":"2026-09-16 18:39","pubTimestamp":1789555160,"startTime":"0","endTime":"0","summary":"石药集团(01093)发布公告，集团开发的SYH2069注射液(“该产品”)用于治疗成人2型糖尿病的II期临床试验(SYH2069-003)已在中国首个研究中心正式启动。","market":"hk","thumbnail":"https://img.zhitongcaijing.com/gonggaonew/ganggugongg6.jpg?x-oss-process=image/format,jpg/quality,Q_100/resize,h_300","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/gonggaonew/ganggugongg6.jpg?x-oss-process=image/format,jpg/quality,Q_100/resize,h_300"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1496940.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1515","SG9999004220.SGD","IE0008369823.USD","LU1226288253.USD","01093","LU0072913022.USD","KURE","LU1226288170.HKD","LU1813983027.USD","BMED","LU1226287529.USD","LU2039709279.SGD","IE00B543WZ88.USD","BK1521","LU0067412154.USD","IE00BZ08YR35.GBP","LU1960683339.HKD","LU1226287875.USD","IE00B5MMRT66.SGD","LU0314109678.HKD","LU1328277881.USD","IE00B031HY20.USD","IE00BZ08YT58.USD","IBBJ","LU1226287792.SGD","BK1191","LU1993786604.SGD","IE00BZ08YS42.EUR","LU1152091168.USD","LU0501845795.SGD","LU0140636845.USD","LU1008478684.HKD","LU0326950275.SGD","HK0000165453.HKD","LU1951186391.HKD","IBBQ","LU0315179316.USD","MDTX","PSYK","IE0008368742.USD","LU1807302812.USD","LU1152091754.HKD","LU0880133367.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667601469","title":"苑東生物：EP-0226片完成I期臨床試驗 推進II期籌備","url":"https://stock-news.laohu8.com/highlight/detail?id=2667601469","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667601469?lang=zh_tw&edition=fundamental","pubTime":"2026-09-16 17:36","pubTimestamp":1789551391,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IBBJ","PSYK","BMED","IBBQ","MDTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667601451","title":"陽光諾和(688621.SH)：在研項目BTP0427的臨床試驗申請獲得批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2667601451","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667601451?lang=zh_tw&edition=fundamental","pubTime":"2026-09-16 17:34","pubTimestamp":1789551264,"startTime":"0","endTime":"0","summary":"智通财经APP讯，阳光诺和(688621.SH)发布公告，近日，公司及全资子公司江苏诺和必拓新药研发有限公司收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，公司在研项目BTP0427的临床试验申请获得批准。BTP0427拟用于治疗射血分数降低的慢性心力衰竭，适用于心脏收缩功能障碍的慢性心力衰竭患者的对症治疗，作为替代疗法，用于已经接受相同剂量的β受体阻滞剂和窦房结If电流抑制剂联合治疗且病情得到控制的患者。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1496870.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IBBJ","PSYK","688621","BMED","MDTX","BK0216","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667019476","title":"陽光諾和：BTP0427規格I、II獲臨床試驗批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2667019476","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667019476?lang=zh_tw&edition=fundamental","pubTime":"2026-09-16 17:30","pubTimestamp":1789551020,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IBBJ","IBBQ","MDTX","BMED","PSYK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667609196","title":"ST百靈(002424.SZ)子公司糖寧通絡乳膏獲批臨床試驗","url":"https://stock-news.laohu8.com/highlight/detail?id=2667609196","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667609196?lang=zh_tw&edition=fundamental","pubTime":"2026-09-16 17:02","pubTimestamp":1789549346,"startTime":"0","endTime":"0","summary":"智通财经APP讯，ST百灵(002424.SZ)发布公告，近日，公司全资子公司百灵毓秀(珠海)医药有限公司(简称“百灵毓秀”)收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，公司糖宁通络乳膏临床试验申请符合药品注册的有关要求，在进一步完善临床试验方案的基础上，同意开展用于糖尿病足溃疡的临床试验。本次公司全资子公司百灵毓秀收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，同意糖宁通络乳膏开展用于糖尿病足溃疡的临床试验，系公司糖宁通络管线重要阶段性研发成果，有利于推进公司糖尿病并发症“内服+外用”治疗体系布局，糖宁通络乳膏获得临床试验批准暂不会对公司当期业绩产生重大影响。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1496831.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0028","BK0239","BK0077","002424","IBBJ","BMED","BK0188","MDTX","BK0183","PSYK","IBBQ","BK0146"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667099276","title":"ST百靈：全資子公司獲2026年藥物臨床試驗批准通知書","url":"https://stock-news.laohu8.com/highlight/detail?id=2667099276","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667099276?lang=zh_tw&edition=fundamental","pubTime":"2026-09-16 16:59","pubTimestamp":1789549183,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IBBQ","PSYK","BMED","IBBJ","MDTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667605559","title":"港股異動 | 恒瑞醫藥(01276)尾盤漲近4% 同日獲兩份臨床試驗批准 覆蓋銀屑病和卒中預防","url":"https://stock-news.laohu8.com/highlight/detail?id=2667605559","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667605559?lang=zh_tw&edition=fundamental","pubTime":"2026-09-16 15:49","pubTimestamp":1789544947,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，恒瑞医药尾盘涨近4%。截至发稿，涨3.88%，报45.5港元，成交额1.53亿港元。消息面上，9月15日，恒瑞医药公告称，子公司福建盛迪医药的HRS-4139片获国家药监局临床试验批准，同意开展中重度斑块状银屑病的临床试验。同日，子公司广东恒瑞医药的注射用瑞卡西单抗获临床试验批准，同意开展Ⅲ期临床试验，适应证为用于颅内动脉粥样硬化性狭窄的成人患者以降低卒中复发风险。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1496770.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1655091616.SGD","LU2097828631.EUR","BK0188","KCAI","BK0012","BK1191","BMED","LU0359201885.HKD","BK0196","BK0028","MDTX","LU2097828474.EUR","LU2097828557.USD","LU2148510915.USD","LU2097828714.EUR","LU2543165471.USD","LU2289578879.USD","LU1997245177.USD","IBBJ","LU1064131003.USD","LU1255011170.USD","LU1781817850.SGD","LU1997245094.SGD","LU1820825898.SGD","LU2097828805.USD","600276","LU2580892862.HKD","LU1328615791.USD","LU2328871848.SGD","BK4588","BK4585","LU2488822045.USD","LU1997244956.HKD","VXUS","LU2580892789.USD","BK0060","LU0359201612.USD","LU1146622755.USD","BK0183","LU2495084118.USD","BK0239","LU1969619763.USD","PSYK","IBBQ","LU0405327148.USD","LU0405327494.USD","01276","LU0359202008.SGD","LU1580142542.USD","LU1023057109.AUD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667724676","title":"創新藥概念股表現活躍","url":"https://stock-news.laohu8.com/highlight/detail?id=2667724676","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667724676?lang=zh_tw&edition=fundamental","pubTime":"2026-09-16 13:18","pubTimestamp":1789535894,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IBBQ","MEDX","LNGR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667672921","title":"香港施政報告：邀請廣深企業參與大學城建設 河套大灣區國際臨床試驗所投入運作","url":"https://stock-news.laohu8.com/highlight/detail?id=2667672921","media":"港股一线","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667672921?lang=zh_tw&edition=fundamental","pubTime":"2026-09-16 13:07","pubTimestamp":1789535220,"startTime":"0","endTime":"0","summary":"李家超指，将邀请广深创新及科技园有限公司及新田科技城有限公司加入开发行列，参与大学城建设，以加快项目建造发展。李家超同时表示，河套香港园区的粤港澳大湾区国际临床试验所已投入运作，由香港特区政府全资拥有并委托香港大学营运，与深圳园区协同推动医疗创新。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/hkyx/2026-09-16/doc-iniryzmc4906916.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["IBBQ","IBBJ","BMED","PSYK","159983","MDTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667674545","title":"江小涓：這個數據大家不要吃驚，未來幾年還要漲","url":"https://stock-news.laohu8.com/highlight/detail?id=2667674545","media":"凤凰网港股","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667674545?lang=zh_tw&edition=fundamental","pubTime":"2026-09-16 11:44","pubTimestamp":1789530285,"startTime":"0","endTime":"0","summary":"江小涓表示，我国创新药产业正迎来全球化爆发新阶段，产业规模与国际影响力持续攀升。江小涓解释，依托AI平台找到治病靶点、匹配新化合物，我国拥有了新药青苗，成果本身很好，但还只是一棵青苗，还需要把好苗对外授权进行进一步培育和商业化。江小涓进一步解释，AI会使产业链出现一些变化。江小涓说，“所以AI for Science不仅仅是我们把自己做好，还会引起全球产业链非常快速的调整，这些行业都是如此，这是一个非常大的变化。”","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://original.ifeng.com/c/8wSeX6t1BpL","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARTY","VTHR","AIPO","CHAT","IBBQ","BK1161","MEDX","QTOC","LNGR","AGIX","06978","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667617679","title":"創新藥概念局部走強 恒瑞醫藥（01276）漲2.74% 機構料企業扭虧節點到來","url":"https://stock-news.laohu8.com/highlight/detail?id=2667617679","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667617679?lang=zh_tw&edition=fundamental","pubTime":"2026-09-16 10:20","pubTimestamp":1789525259,"startTime":"0","endTime":"0","summary":"消息面上，国金证券表示，创新药企业扭亏节点到来，全年临床数据催化密集，叠加已BD出海管线海外临床进展顺利，看好创新药板块投资机会。诚通证券表示，2025年为创新药海外授权BD大年，2026H1我国创新药海外授权BD交易继续大幅增长，总交易金额已接近1000亿美元，国产创新药已从偶发性出海转变为系统性趋势。","market":"hk","thumbnail":"https://static.szfiu.com/news/20250110/NTQxOTRlZTU5ZGZkZjc4MmEzMTdjMTVhMTM1NjYxOTg3NzU=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/NTQxOTRlZTU5ZGZkZjc4MmEzMTdjMTVhMTM1NjYxOTg3NzU=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"299f0a9977df499f8ead781071e5e5e7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1991724","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0516423174.USD","LU0348827113.USD","LNGR","LU2148510915.USD","LU1328615791.USD","LU0043850808.USD","09688","BK0060","01477","159992","LU0307460666.USD","01177","06978","LU0359201612.USD","LU1655091616.SGD","BK1574","LU1255011170.USD","BK1515","LU0456846285.SGD","LU0516422952.EUR","KURE","LU2097828557.USD","LU0327786744.USD","LU0417516902.SGD","LU1023057109.AUD","MEDX","IE00BZ08YS42.EUR","IE00B0JY6N72.USD","LU0405327148.USD","LU2039709279.SGD","LU0588546209.SGD","LU2097828805.USD","600276","LU0140636845.USD","LU0128526141.USD","02269","LU0561508036.HKD","LU2580892789.USD","LU1820825898.SGD","LU1997244956.HKD","BK0188","BK0183","LU2488822045.USD","LU1146622755.USD","LU1580142542.USD","01276","LU0348825331.USD","IBBQ","02637","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667267605","title":"百時美施貴寶就安進擬推出的Opdivo生物類似藥提起訴訟","url":"https://stock-news.laohu8.com/highlight/detail?id=2667267605","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667267605?lang=zh_tw&edition=fundamental","pubTime":"2026-09-16 10:15","pubTimestamp":1789524901,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LU1868836757.USD","LU1992135399.USD","PJP","LU0114720955.EUR","LU2125154778.USD","BIB","AMGN","LU0289739699.SGD","BK4566","LU2473716301.USD","XPH","IBBQ","LU1236620834.HKD","LU2272731600.USD","LU2468319806.SGD","BK4139","LU1023059063.AUD","LU0320765992.SGD","PBE","IE00BSNM7G36.USD","LU1989771016.USD","FTXH","LU1236620750.USD","LU1670711123.USD","LU0058720904.USD","PPH","LU0868494617.USD","TBXU","LU1868836591.USD","BBH","LU0225284248.USD","IE00B4R5TH58.HKD","IHE","IE0009355771.USD","BK4585","LU2272731865.HKD","LU1868837300.USD","LU0109394709.USD","LU0061475181.USD","LU1983299246.USD","BK4588","LU1883839398.USD","LU2322448957.HKD","LU1261432733.SGD","BK4559","BK4533","IBB","BK4534","BMY","LU0225771236.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667204626","title":"恒瑞醫藥(01276.HK)：注射用瑞卡西單抗獲得藥物臨床試驗批准通知書","url":"https://stock-news.laohu8.com/highlight/detail?id=2667204626","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667204626?lang=zh_tw&edition=fundamental","pubTime":"2026-09-16 07:38","pubTimestamp":1789515492,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["MDTX","BMED","IBBQ","IBBJ","PSYK"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":11,"pageCount":1,"totalSize":215,"code":"91000000","status":"200"}]}}